参考文献: [1]SchmittelA.Controversiesinthetreatmentofadvancedstagesofsmallcelllungcancer[J].FrontRadiatTherOncol,2010,42:193-197.DOI:10.1159/000262476. [2]刘小小&张中冕.(2021).SCLC脑转移治疗进展.现代肿瘤医学(23),4234-4237. [3]HochstenbagMM,T...
参考文献: [1]SchmittelA.Controversiesinthetreatmentofadvancedstagesofsmallcelllungcancer[J].FrontRadiatTherOncol,2010,42:193-197.DOI:10.1159/000262476. [2]刘小小&张中冕.(2021).SCLC脑转移治疗进展.现代肿瘤医学(23),4234-4237. [3]HochstenbagMM,TwijnstraA,WilminkJT,etal.Asymptomaticbrainmetastases(BM...
The staging system for SCLC is divided into limited stage (stages I to III; LS-SCLC) and extensive stage (IV; ES-SCLC). Appropriate staging studies include history and physical, CT scans of chest/abdomen, and MRI of the brain. LS-SCLC occurs approximately one third of the time with ES-...
and LC is still the leading cause of cancer deaths[1]. SCLC accounts for 15%–20% of the total number of LC, whcih is featured by high malignancy, strong invasiveness
stage, the time and context of other therapeutic variables in which surgery would result in a favorable outcome.A selective literature search was performed in PubMed based on the following key words: surgery, small cell lung cancer (SCLC) and multimodal therapy strategies for the treatment of ...
Small cell lung cancer (SCLC) accounts for 15%–20% of all cases and is the most aggressive type of lung cancer (LC). It is classified into two stages: limited stage (LS-SCLC) and ES-SCLC, with both exhibiting high malignancy, strong invasiveness, early metastasis, fast disease progressio...
Retrospectivestudywascarriedon93patientswithsmallcelllungcancerinextensive—stagefromOctoberof2008toOctoberof2010inShaanxiProvinceTumorHospita1.Themuhiva-riateanalysiswasperformedwithCox§proportionriskmode1.Toanalyzethegeneralstatus,stages,PSscore,metastat—icsites,chemotherapycycles,prophylacticcranialirradiation,...
Loss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests selective pressure to inactivate cell death pathways prior to therapy. Yet, which of these pathways remain available in treatment-naïve SCLC is unknown. Here, through systemic analysis of cell death pathway availa...
Learn about TECENTRIQ® (atezolizumab), a cancer Immunotherapy treatment for Non-Small Cell Lung Cancer after surgery and chemo, Metastatic Non-Small Cell Lung Cancer (NSCLC), Extensive-Stage Small Cell Lung Cancer (ES-SCLC), Liver cancer (HCC), & Adva
Ahn stressed that durvalumab's success in both extensive and limited stages of SCLC marks it as the first therapeutic option to demonstrate such efficacy across these stages. “The advancements signal a potential overall improvement in survival rates for lung cancer patients," Ahn said. "With durva...